Red Lapacho (Tabebuia impetiginosa)-A global ethnopharmacological commodity?

Journal of Ethnopharmacology

Volumn 121, Issue 1, 2009, Pages 1-13

  Gómez Castellanos, J Rubén ^a   Prieto, José M ^a   Heinrich, Michael ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Anti cancer agents; Drug history; Red Lapacho (Pau d'arco); Tabebuia impetiginosa

Indexed keywords

ARQ 501; BETA LAPACHONE; FARNOQUINONE; HERBACEOUS AGENT; LAPACHOL; RED LAPACHO; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG ISOLATION; DRUG MARKETING; DRUG METABOLISM; DRUG QUALITY; DRUG RESEARCH; DRUG STRUCTURE; DRUG USE; ETHNOBOTANY; ETHNOPHARMACOLOGY; HEAD AND NECK CARCINOMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LEIOMYOSARCOMA; NONHUMAN; PANCREAS CANCER; REVIEW; TABEBUIA; THROMBOCYTE AGGREGATION INHIBITION; VASCULAR SMOOTH MUSCLE; VITAMIN K METABOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; HUMANS; MEDICINE, TRADITIONAL; NEOPLASMS; PHYTOTHERAPY; PLANT BARK; PLANT EXTRACTS; SOUTH AMERICA; TABEBUIA;

BACTERIA (MICROORGANISMS); TABEBUIA AVELLANEDAE; TABEBUIA IMPETIGINOSA;

EID: 58049131225     PISSN: 03788741     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jep.2008.10.004     Document Type: Review

References (118)

1. Anesisni C., and Pérez C. Screening of plants used in Argentine folk medicine for antimicrobial activity. Journal of Ethnopharmacology 39 (1993) 119-128
2. ArQule, 2008a. ARQ 501 in combination with gemcitabine in subjects with pancreatic cancer (NCT00102700). ClinTrials.gov http://clinicaltrials.gov/ct2/show/NCT00102700.
3. ArQule, 2008b. Safety and efficacy study of ARQ 501 in adult patients with leiomyosarcoma (NCT00310518). ClinTrials.gov http://clinicaltrials.gov/ct2/show/NCT00310518.
4. ArQule, 2008c. A study of ARQ 501 in patients with squamous cell carcinoma of the head and neck (NCT00358930). ClinTrials.gov http://clinicaltrials.gov/ct2/show/NCT00358930.
5. Begleiter A., and Fourie J. Induction of NQO1 in cancer cells. Methods in Enzymology 382 (2004) 320-351
6. Blatt C.T.T., Salatino A., and Salatino M.F. Flavonoids of Tabebuia caraiba (Bignoniaceae). Biochemical Systematics and Ecology 24 (1996) 89
7. Block J.B., Serpick A.A., Miller W., and Wiernik P.H. Early clinical studies with lapachol (NSC-11905). Cancer Chemotherapy Reports Part 2 (1974) 27-28
8. Boik J. Nonflavonoid Phenolic Compounds. Natural Compounds in Cancer Chemotherapy (2001), Oregon Medical Press, Princeton p. 286
9. Boorstein R.J., and Pardee A. β-Lapachone greatly enhances NMS lethality to human fibroblasts. Biochemical and Biophysical Research Communications 118 (1984) 828-834
10. Booth S.L., and Suttie J.W. Dietary intake and adequacy of vitamin K. Journal of Nutrition 128 (1998) 785-788
11. Boothman D.A., Greer S., and Pardee A.B. Potentiation of halogenated pyrimidine radiosensitizers in human carcinoma cells by beta-lapachone (3,4-dyhydro-2,2-dimethyl-2H-naphtol[1,2-b]pyran-5,6-dione), a novel DNA repair inhibitor. Cancer Research 47 (1987) 5361-5366
12. Boothman D.A., Meyers M., Fukunaga N., and Lee S.W. Isolation of X-ray-inducible transcripts from radioresistant human melanoma cells. Proceedings of the National Academy of Sciences of the United States of America 90 (1993) 7200-7204
13. Boothman D.A., Trask D.K., and Pardee A.B. Inhibition of potentially lethal DNA damage repair in human tumour cells by beta-lapachone, an activator of topoisomerase I. Cancer Research 49 (1989) 605-612
14. Brody T. Nutritional Biochemistry (1999), Academic Press, San Diego p. 1006
15. Buettner G.R. The pecking order of free radicals and antioxidants: lipid peroxidation, α-tocopherol, and ascorbate. Archives of Biochemistry and Biophysics 300 (1993) 535-543
16. Cadenas E. Antioxidant and prooxidant functions of DT-diaphorase in quinone metabolism. Biochemical Pharmacology 49 (1995) 127-140
17. Calixto J.B. Twenty-five years of research on medicinal plants in Latin America: a personal view. Journal of Ethnopharmacology 100 (2005) 131-134
18. Cassady J.M., and Douros J.D. Miscellaneous Natural Products with Antitumor Activity. Anticancer Agents Based on Natural Product Models (1980), Academic Press, New York p. 474
19. Cragg G.M., and Newman D.J. Plants as a source of anticancer agents. Journal of Ethnopharmacology 100 (2005) 72-79
20. Cresteil T., and Jaiswel K. High levels of expression of the NAD(P)H:Quinone oxidoredectase (NQO1) gene in tumor cells compared to normal cells of the same origin. Biochemical Pharmacology 42 (1991) 1021-1027
21. Cunningham, C.C., 2008. ARQ 501 in combination with docetaxel in patients with cancer (NCT00099190). ClinTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT00099190.
22. da Consolaçào M., Linardi F., de Oliveira M.M., and Sampaio M.R.P. Lapachol derivatives active against mouse lymphocytic leukemia. Journal of Medicinal Chemistry 18 (1975) 1159-1161
23. de Montmorency A. South American Cancer Cure (1981), The Spotlight, Washington, DC
24. de Oliveira A.B., Raslan D.S., de Oliveira G.G., and Maia J.G.S. Lignans and naphthoquinones from Tabebuia incana. Phytochemistry 34 (1993) 1409-1412
25. Díaz F., and Medina J.D. Furanonaphthoquinones from Tabebuia ochracea ssp. neochrysanta. Journal of Natural Products 59 (1996) 423-424
26. Dixon A.R., McMillen H., and Etkin N.L. Ferment this: the transformation of noni, a traditional polynesian medicine (Morinda citrifolia, Rubiaceae). Economic Botany 53 (1999) 51-68
27. Dos Santos E.V.M., Carneiro J.W.M., and Ferreira V.F. Quantitative structure-activity relationship in aziridinyl-1,4-naphthoquinone antimalarials: study of theoretical correlations by the PM3 method. Bioorganic and Medicinal Chemistry 12 (2004) 87-93
28. Dubin M., Fernández V.S., and Stoppani A.O. Inhibition of microsomal lipid peroxidation and cytochrome P-450-catalyzed reactions by beta-lapachone and related naphthoquinones. Biochemical Pharmacology 39 (1990) 1151-1160
29. Duke J.A. CRC Handbook of Medicinal Herbs (1985), CRC, Boca Ratón p. 470
30. FDA, 1999. Economic characterization of the dietary supplement industry. Final Report. Center for Food Safety and Applied Nutrition, United States Food and Drug Administration.
31. Fry M., and Pudney M. Site of action of the antimalarial hydroxynaphtaquinone-2-[trans-4-(49-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80). Biochemical Pharmacology 43 (1992) 1545-1553
32. Furie B., Bouchard B.A., and Furie B.C. Vitamin K-dependant biosynthesis of gamma-carboxyglutamic acid. Blood 93 (1999) 1798-1808
33. García Barriga H. Flora Medicinal de Colombia. Botánica Médica (1992), Tercer Mundo Editores, Bogotá pp. 142-148
34. Gately S.K.R. Therapeutic potential of selective cyclooxigenase-2 inhibitors in the management of tumor angiogenesis. Progress in Experimental Tumor Research 37 (2003) 179-192
35. Gonçalves A.M., Vasconcellos M.E., Docampo R., Cruz F.S., de Souza W., and Leon W. Evaluation of the toxicity of 3-allyl-β-lapachone against Trypanosoma cruzi bloodstream forms. Molecular and Biochemical Parasitology 1 (1980) 167-176
36. Guiraud P., Steiman R., Campos-Takaki G.M., Seigle-Murandi F., and Bouchberg M. Comparison of antibacterial and antifungal activities of lapachol and β-lapachone. Planta Medica 6 (1994) 373-374
37. Hartwell L.H., and Weinert T.A. Checkpoints: controls that ensure the order of cell cycle events. Science 246 (1989) 629-634
38. Heinrich M. Roter Lapacho-Tee. Zeitschrift für Phytotherapie 19 (1998) 99-100
39. Heinrich M., Heneka B., Ankli A., Rimpler H., Sticher O., and Kostiza T. Spasmolytic and antidiarrhoeal properties of the Yucatec Mayan medicinal plant Casimiroa tetrameria. The Journal of Pharmacy and Pharmacology 57 (2005) 1081-1085
40. Heinrich M., and Prieto J.M. Diet and healthy ageing 2100: will we globalise local knowledge systems?. Ageing Research Reviews 7 (2008) 249-274
41. Henry T.R., and Wallace K.B. Differential mechanisms of induction of the mitochondrial permeability transition by quinones of varying chemical reactivities. Toxicology and Applied Pharmacology 134 (1995) 195-205
42. Hsiang Y.H., Hertzberg R., Hecht S., and Liu L.F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. Journal of Biological Chemistry 260 (1985) 14873-14878
43. Jaeger A. Is traditional medicine better off 25 years later?. Journal of Ethnopharmacology 100 (2005) 3-4
44. Jones K. Pau d'Arco: Immune Power from the Rain Forest (1995), Healing Arts Press, Rochester pp. 3-15, 33-66
45. Koyama J., Morita I., Tagahara K., and Iría K.J. Cyclopentene dialdehydes from Tabebuia impetiginosa. Phytochemistry 53 (2000) 869-872
46. Lee J.H., Cheong J.H., Park Y.M., and Choi Y.H. Down-regulation of cyclooxigenase-2 and telomerase activity by β-lapachone in human prostate carcinoma cells. Pharmacological Research 51 (2005) 553-560
47. Li C.J., Averboukh L., and Pardee A.B. β-Lapachone, a novel DNA topoisomerase I inhibitor with a mode of action different from camptothecin. Journal of Biological Chemistry 268 (1993) 22463-22468
48. Li Y., Sun X., LaMont J.T., Pardee A.B., and Li C.J. Selective killing of cancer cells by β-lapachone: direct checkpoint activation as a strategy against cancer. Proceedings of the National Academy of Sciences of the United States of America 100 (2002) 2674-2678
49. Li C.J., Wang C., and Pardee A.B. Induction of apoptosis by beta-lapachone in human prostate cancer cells. Cancer Research 55 (1995) 3712-3715
50. Luebeck W. The Healing Power of Pau d'Arco (1999), Lotus Press pp. 17-29
51. Malkinson A.M., Siegel D., Forrest G.L., Gazdar A.F., Oie H.K., Chan D.C., Bunn P.A., Mabry M., Dykes D.J., Harrison S.D., and Ross D. Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumor xenografts to mitomycin Cl. Cancer Research 52 (1992) 4752-4757
52. Manners G.D., and Jurd L. A new naphthoquinone from Tabebuia guayacan. Phytochemistry 15 (1976) 225-226
53. Mans D.R.A., da Rocha A.B., and Schwartsmann G. Anti-cancer drug discovery and development in Brazil: targeted plant collection as a rational strategy to acquire candidate anticancer compounds. The Oncologist 5 (2000) 185-198
54. MHRA, 2005a. Safety of Herbal Medicines. On line document available in: http://www.mhra.gov.uk/home/groups/is-pol/documents/websiteresources/con009277.pdf.
55. MHRA, 2005b. Traditional Herbal Medicines Registration Scheme. UK Medicines and Healthcare Products Regulatory Agency.
56. Miao X.S., Song P., Savage R.E., Zhong C., Yang R.Y., Kizer D., Wu H., Volckova E., Ashwell M.A., Supko J.G., He X., and Chan T.C.K. Identification of the in vitro metabolites of 3,4-dihydro-2,2-dimethyl-2H-naphtol[1,2-b]pyran-5,6-dione (ARQ 501; β-lapachone) in whole blood. Drug Metabolism and Disposition 36 (2008) 641-648
57. Mowrey D.B. Herbal Tonic Therapies (1996), Gramercy, New York pp. 69-87
58. Mowrey D.B. Ancient Herb, Modern Medicine (2001), Mountainwest Institute of Herbal Sciences, Salt Lake City
59. Müller K., Sellmer A., and Wiegrebe W. Potential antipsoriatic agents: lapacho compounds as potent inhibitors of HaCaT cell growth. Journal of Natural Products 62 (1999) 1134-1136
60. Nahle Z., Polakoff J., Davuluri R.V., McCurrach M.E., Jacobson M.D., Narita M., Zhang M.Q., Lazebnik Y., Bar-Sagi D., and Lowe S.W. Direct coupling of the cell cycle and cell death machinery by E2F. Nature Cell Biology 4 (2002) 859-864
61. O'Brien P.J. Molecular mechanisms of quinone cytotoxicity. Chemico-Biological Interactions 80 (1991) 1-41
62. Oswald E.H. Lapacho. British Journal of Phytotherapy 3 (1993) 112-117
63. Pardee A.B. G1 events and regulation of cell proliferation. Science 246 (1989) 433-439
64. Pardee A.B., Li Y.Z., and Li C.J. Cancer therapy with β-lapachone. Current Cancer Drug Targets 2 (2002) 227-242
65. Pardo de Santayana M., Blanco E., and Morales R. Plants known as té in Spain: an ethno-pharmaco-botanical review. Journal of Ethnopharmacology 98 (2005) 1-19
66. Park H.J., Ahn K.I., Ahn S.D., Choi E., Lee S.W., Williams B., Kim E.J., Griffin R., Bey E.A., Bornmann W.G., Gao J., Park H.J., Boothman D.A., and Song C.W. Susceptibility of cancer cells to β-lapachone is enhanced by ionizing radiation. International Journal of Radiation Oncology, Biology, Physics 61 (2005) 212-219
67. Park B.S., Kim J.R., Lee S.E., Kim K.S., Takeoka G.R., Ahn Y.J., and Kim J.H. Selective growth-inhibiting effects of compounds identified in Tabebuia impetiginosa inner bark on human intestinal bacteria. Journal of Agricultural and Food Chemistry 53 (2005) 1152-1157
68. Park B.S., Lee H.K., Lee S.E., Piao X.L., Takeoka G.R., Wong R.Y., Ahn Y.J., and Kim J.H. Antibacterial activity of Tabebuia impetiginosa Martius ex DC (Taheebo) against Helicobacter pylori. Journal of Ethnopharmacology 105 (2006) 255-262
69. Park B.S., Lee K.W., and Takeoka G.R. Comparison of three sample preparation methods on the recovery of volatile from Taheebo (Tabebuia impetiginosa Martius ex DC). Flavour and Fragrance Journal 19 (2004) 287-292
70. Pérez Sacau E., Estévez-Braun A., Ravelo A.G., Ferro E.A., Tokuda H., Mukainaka T., and Nishino H. Inhibitory effects of lapachol derivatives on Epstein-Barr virus activation. Bioorganic and Medicinal Chemistry 11 (2003) 483-488
71. Pink J.J., Planchon S.M., Tagliarino C., Varnes M.E., Siegel D., and Boothman D.A. NAD(P)H:Quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity. Journal of Biological Chemistry 275 (2000) 5416-5424
72. Pink J.J., Wuerzberger-Davis S., Tagliarino C., Planchon S.M., Yang X.H., Froelich C.J., and Boothman D.A. Activation of a cysteine protease in MCF-7 and T47D breast cancer cells during β-lapachone-mediated apoptosis. Experimental Cell Research 255 (2000) 144-155
73. Planchon S.M., Pink J.J., Tagliarino C., Bornmann W.G., Varnes M.E., and Boothman D.A. β-Lapachone-induced apoptosis in human prostate cancer cells: involvement of NQO1/xip3. Experimental Cell Research 267 (2001) 95-106
74. Planchon S.M., Wuerzberger S., Frydman B., Witiak D.T., Hutson P., Church D.R., Wilding G., and Boothman D.A. β-Lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response. Cancer Research 55 (1995) 3706-3711
75. Portillo A., Vila R., Freixa B., Adzet T., and Cañigueral S. Antifungal activity of Paraguayan plants used in traditional medicine. Journal of Ethnopharmacology 76 (2001) 93-98
76. Posey D.A. Commodification of the sacred through intellectual property rights. Journal of Ethnopharmacology 83 (2002) 3-12
77. Rao K.V., McBride T.J., and Oleson J.J. Recognition and evaluation of lapachol as an antitumor agent. Cancer Research 28 (1968) 1952-1954
78. Ravelo A.G., Estévez-Braun A., Chávez-Orellana H., Pérez-Sacau E., and Mesa-Silverio D. Recent studies on natural products as anticancer agents. Current Topics in Medicinal Chemistry 4 (2004) 241-265
79. Savage R.E., Tyler A.N., Miao X.S., and Chan T.C.K. Identification of a novel glucosylsulfate conjugate as a metabolite of 3,4-dihydro-2,2-dimethyl-2H-naphto[1,2b]pyran-5,6-dione (ARQ 501; β-lapachone) in mammals. Drug Metabolism and Disposition 36 (2008) 753-758
80. Schuerch A.R., and Wehrli W. beta-lapachone, an inhibitor of oncornavirus reverse transcriptase and eukaryotic DNA polymerase-alpha. Inhibitory effect, thiol dependence and specificity. European Journal of Biochemistry 84 (1978) 197-205
81. Schultes R.E., and Raffauf R.F. The healing forest. Medicinal and toxic plants of the Northwest Amazonia. In: Dudley T.R. (Ed). Historical, Ethno- & Economic Botany Series (1990), Dioscorides Press, Portland 107-109
82. Schwontkowski D. Herbs of the Amazon. Traditional and Common Uses (1993), Science Student Brain Trust Publishing
83. Sears R.C., and Nevins J.R. Signaling networks that link cell proliferation and cell fate. Journal of Biological Chemistry 277 (2002) 11617-11620
84. Senzer, N.N., 2008. An extension study for patients previously treated with ARQ 501 (NCT00622063). ClinTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT00622063.
85. Shapiro, G., 2008a. An exploratory biomarker study of ARQ 501 in patients with advanced solid tumors (NCT00524524). ClinTrials.gov http://clinicaltrials.gov/ct2/show/NCT00524524.
86. Shapiro, G.I., Cunningham, C.C., 2008b. ARQ 501 in subjects with cancer (ARQ 501 in subjects with cancer) (NCT00075933). ClinTrials.gov http://clinicaltrials.gov/ct2/show/NCT00075933.
87. Sharma P.K., Khanna R.N., Rohatgi B.K., and Thomson R.H. Tecomaquinone-III: a new naphthoquinone from Tabebuia pentaphylla. Phytochemistry 27 (1988) 632-633
88. Shearer M.J. Vitamin K. Lancet 345 (1995) 229
89. Shearer M.J. The roles of vitamins D and K in bone health and osteoporosis prevention. The Proceedings of the Nutrition Society 56 (1997) 915-937
90. Shiah S.G., Chuang S.E., Chau Y.P., Shen S.C., and Kuo M.L. Activation of c-Jun NH2-terminal kinase and subsequent CPP32/Yama during topoisomerase inhibitor β-lapachone-induced apoptosis through an oxidation-dependant pathway. Cancer Research 59 (1999) 391-1391
91. Simamura E., Hirai K.I., Shimada H., Pan J., and Koyama J. Mitochondrial damage prior to apoptosis in furanonaphthoquinone treated lung cancer cells. Cancer Detection and Prevention 27 (2003) 5-13
92. Smith W.L., DeWitt D.L., Garavito R.M., and Garavito R.M. Cyclooxigenases: structural, cellular, and molecular biology. Annual Review of Biochemistry 69 (2000) 145
93. Son D.J., Lim Y., Park Y.H., Chang S.K., Yun Y.P., Hong J.T., Takeoka G.R., Lee K.G., Lee S.E., Kim M.R., Kim J.H., and Park B.S. Inhibitory effects of Tabebuia impetiginosa inner bark extract on platelet aggregation and vascular smooth muscle cell proliferation through suppressions of arachidonic acid liberation and ERK1/2 MAPK activation. Journal of Ethnopharmacology 108 (2006) 148-151
94. Steinert J., Khalaf H., and Rimpler M. HPLC separation and determination of naphtol[2,3-b]furan-4,9-diones and related compounds in extracts of Tabebuia avellanedae (Bignonaceae). Journal of Chromatography A 693 (1995) 281-287
95. Steinert J.K.H., and Rimpler M. High-performance liquid chromatographic separation of some naturally occurring naphthoquinones and anthraquinones. Journal of Chromatography A 723 (1996) 206-209
96. Stratton M.S., and Alberts D.S. Current application of selective COX-2 inhibitors in cancer prevention and treatment. Oncology (Williston Park) 16 (2002) 37-51
97. Suffnes M., and Douros J.D. Miscellaneous natural products with antitumor activity. In: Cassady J.M., and Douros J.D. (Eds). Anticancer Agents Based on Natural Product Models (1980), Academic Press, New York p474
98. Suttie J.W. Vitamin K. In: Ziegler E.E., and Filer L.J. (Eds). Present Knowledge in Nutrition (1996), ILSI Press, Washington 137-145
99. Tagliarino C., Pink J.J., Dubyak G.R., Nieminem A.L., and Boothman D.A. Calcium is a key signaling molecule in β-lapachone-mediated cell death. Journal of Biological Chemistry 276 (2001) 1950-1959
100. Taylor L. The Healing Power of Rainforest Herbs (2005), Square One Publishers, Garden City Park
101. Thomson R.H. Naphtaquinones. Naturally Occurring Quinones (1971), Academic Press, London p. 203
102. Thomson R.H. Naturally Occurring Quinones. III. Recent Advances (1987), Chapman and Hall, Cambridge p. 203
103. Trimarchi J.M., and Lees J.A. Sibling rivalry in the E2F family. Nature reviews. Molecular Cell Biology 3 (2002) 11-20
104. Tyler V.E. Tyler's Honest Herbal (1999), The Haworth Herbal Press, Binghamton pp. 287-291
105. Umar A., Viner J.L., Anderson W.F., and Hawk E.T. Development of COX inhibitors in cancer prevention and therapy. American Journal of Clinical Oncology 26 (2003) 48-57
106. Verpoorte R., Choi Y.H., and Kim H.K. Ethnopharmacology and systems biology: a perfect holistic match. Journal of Ethnopharmacology 100 (2005) 53-56
107. Voet D., and Voet J.G. The Expression and Transmission of Genetic Information. Biochemistry (1995), John Wiley and Sons, New York pp. 879-882
108. Volgstein B., Lane D., and Levine A.J. Surfing the p53 network. Nature 408 (2000) 307-310
109. Wagner H., Kreher B., Lotter H., Hamburger M.O., and Cordell G.A. Structure determination of new isomeric naphtho[2,3-b]furan-4,9-diones from Tabebuia avellanedae by the selective-INEPT technique. Helvetica Chimica Acta 72 (1989) 659-667
110. Walters R. Options: The Alternative Cancer Therapy Book (1993), Avery, Honesdale pp. 128-135
111. Wang J.C. DNA topoisomerases. Annual Review of Biochemistry 54 (1985) 665-697
112. Warashina T., Nagatani Y., and Noro T. Constituents from the bark of Tabebuia impetiginosa. Phytochemistry 65 (2004) 2003-2011
113. Warashina T., Nagatani Y., and Noro T. Further constituents from the bark of Tabebuia impetiginosa. Phytochemistry 66 (2005) 589-597
114. Warashina T., Nagatani Y., and Noro T. Constituents from the bark of Tabebuia impetiginosa. Chemical and Pharmaceutical Bulletin 54 (2006) 14-20
115. Wichtl, M. (Ed.), 2002. Teedrogen und Phytopharmaka. Ein Handbuch für die Praxis auf wissenschaftlicher Grundlage. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
116. Wuerzberger S., Pink J.J., and Planchon S.M. Induction of apoptosis in MCF-7: WS8 breast cancer cells by beta-lapachone. Cancer Research 58 (1998) 1876-1885
117. Zani C.L., de Oliveira A.B., and de Oliveira G.G. Furanonaphthoquinones from Tabebuia ochracea. Phytochemistry 30 (1991) 2379-2381
118. Zhou B.B., and Elledge S.J. The DNA damage response: putting checkpoints in perspective. Nature 408 (2000) 339-433